BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...at Clementia Pharmaceuticals Inc., acquired by Ipsen Group (Euronext:IPN; Pink:IPSEY) in 2019. Mark Kirschbaum joined cancer company Cyclacel Pharmaceuticals Inc....
BioCentury | Aug 28, 2020
Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

...companies have disclosed cancer programs targeting p27. Neither Cyclacel Pharmaceuticals Inc....
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

...inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy closer to the clinic, and Cyclacel...
...for FMTs (see “Seeking Safe Microbiome Therapies Amid COVID-19 Crisis” ). Cyclacel, Edinburgh’s CDK inhibitors Cyclacel Pharmaceuticals Inc....
...cell differentiation protein TLR4 - Toll-like receptor 4 Elizabeth S. Eaton, Staff Writer Ultomiris, ravulizumab-cwvz (ALXN1210) CYC065 Alexion Pharmaceuticals Inc. Cyclacel Pharmaceuticals Inc. University...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...Inc. (NASDAQ:SRPT) 7/24/17 $374.0 $2,711.7 $2,918.1 8% ContraFect Corp. (NASDAQ:CFRX) 7/20/17 $40.0 $92.1 $81.8 -11% Cyclacel Pharmaceuticals Inc....
BioCentury | Aug 17, 2017
Clinical News

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

...3-week cycle. CYC065 is a second-generation inhibitor of cyclin dependent kinase 2 (CDK2) and CDK9. Cyclacel Pharmaceuticals Inc....
...tumors Endpoint: Safety and dose-limiting toxicities (DLTs); pharmacokinetics Status: Phase I data Milestone: NA Elizabeth S. Eaton CYC065 Cyclacel Pharmaceuticals Inc. Cyclin...
BioCentury | Jul 21, 2017
Financial News

Cyclacel raises $13.2M in follow-on

...Cancer company Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) raised $13.2 million through the sale of 2.2 million class A units...
...and warrants to purchase up to 500 shares at $2. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Alex Himes Cyclacel Pharmaceuticals Inc....
BioCentury | Apr 27, 2017
Clinical News

CYC140: Preclinical data

...STPK13) inhibitor. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Product: CYC140 Business: Cancer Indication: Treat cancer Alicia Parker CYC140 Cyclacel Pharmaceuticals Inc. Polo-like...
BioCentury | Apr 13, 2017
Clinical News

CYC065: Preclinical data

...2015 ). Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Product: CYC065 Business: Cancer Indication: Treat lung cancer Julian Zhu CYC065 Cyclacel Pharmaceuticals Inc. Cyclin...
BioCentury | Apr 7, 2017
Finance

Fade to black

...CD101 topical after it fails in the Phase II RADIANT trial to treat vulvovaginal candidiasis Cyclacel Pharmaceuticals Inc....
BioCentury | Feb 24, 2017
Clinical News

Sapacitabine: Additional Ph III SEAMLESS data

...of sapacitabine and Dacogen decitabine missed the primary endpoint of improving OS vs. Dacogen alone. Cyclacel...
...mg sapacitabine twice daily 3 times a week for 2 weeks of a 4-week cycle. Cyclacel...
...approved in the U.S. to treat myelodysplastic syndromes (MDS) and is used off-label for AML. Cyclacel...
Items per page:
1 - 10 of 286
BioCentury | Nov 3, 2020
Management Tracks

Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more

...at Clementia Pharmaceuticals Inc., acquired by Ipsen Group (Euronext:IPN; Pink:IPSEY) in 2019. Mark Kirschbaum joined cancer company Cyclacel Pharmaceuticals Inc....
BioCentury | Aug 28, 2020
Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

...companies have disclosed cancer programs targeting p27. Neither Cyclacel Pharmaceuticals Inc....
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

...inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy closer to the clinic, and Cyclacel...
...for FMTs (see “Seeking Safe Microbiome Therapies Amid COVID-19 Crisis” ). Cyclacel, Edinburgh’s CDK inhibitors Cyclacel Pharmaceuticals Inc....
...cell differentiation protein TLR4 - Toll-like receptor 4 Elizabeth S. Eaton, Staff Writer Ultomiris, ravulizumab-cwvz (ALXN1210) CYC065 Alexion Pharmaceuticals Inc. Cyclacel Pharmaceuticals Inc. University...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...Inc. (NASDAQ:SRPT) 7/24/17 $374.0 $2,711.7 $2,918.1 8% ContraFect Corp. (NASDAQ:CFRX) 7/20/17 $40.0 $92.1 $81.8 -11% Cyclacel Pharmaceuticals Inc....
BioCentury | Aug 17, 2017
Clinical News

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

...3-week cycle. CYC065 is a second-generation inhibitor of cyclin dependent kinase 2 (CDK2) and CDK9. Cyclacel Pharmaceuticals Inc....
...tumors Endpoint: Safety and dose-limiting toxicities (DLTs); pharmacokinetics Status: Phase I data Milestone: NA Elizabeth S. Eaton CYC065 Cyclacel Pharmaceuticals Inc. Cyclin...
BioCentury | Jul 21, 2017
Financial News

Cyclacel raises $13.2M in follow-on

...Cancer company Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) raised $13.2 million through the sale of 2.2 million class A units...
...and warrants to purchase up to 500 shares at $2. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Alex Himes Cyclacel Pharmaceuticals Inc....
BioCentury | Apr 27, 2017
Clinical News

CYC140: Preclinical data

...STPK13) inhibitor. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Product: CYC140 Business: Cancer Indication: Treat cancer Alicia Parker CYC140 Cyclacel Pharmaceuticals Inc. Polo-like...
BioCentury | Apr 13, 2017
Clinical News

CYC065: Preclinical data

...2015 ). Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Product: CYC065 Business: Cancer Indication: Treat lung cancer Julian Zhu CYC065 Cyclacel Pharmaceuticals Inc. Cyclin...
BioCentury | Apr 7, 2017
Finance

Fade to black

...CD101 topical after it fails in the Phase II RADIANT trial to treat vulvovaginal candidiasis Cyclacel Pharmaceuticals Inc....
BioCentury | Feb 24, 2017
Clinical News

Sapacitabine: Additional Ph III SEAMLESS data

...of sapacitabine and Dacogen decitabine missed the primary endpoint of improving OS vs. Dacogen alone. Cyclacel...
...mg sapacitabine twice daily 3 times a week for 2 weeks of a 4-week cycle. Cyclacel...
...approved in the U.S. to treat myelodysplastic syndromes (MDS) and is used off-label for AML. Cyclacel...
Items per page:
1 - 10 of 286